ClinicalTrials.gg
RecruitingNCT06568081Updated Aug 11, 2026

SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study

An interventional study of SloMo in Schizophrenia Spectrum and Other Psychotic Disorders and Affective Psychoses, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Primary conditionAffective Disorders, PsychoticRegistry: Schizophrenia Spectrum and Other Psychotic DisordersReclassifiedWhy we changed it
Registry
Schizophrenia Spectrum and Other Psychotic Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Affective Disorders, Psychotic
Why
  1. The study's listed conditions name Affective Disorders, Psychotic, a narrower term within Schizophrenia Spectrum and Other Psychotic Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by King's College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in the way of life. Cognitive behaviour therapy for psychosis (CBTp) is the recommended talking therapy. However, only a minority of people can access CBTp due to limited resources, and even when available, therapy can be difficult to do and use in daily life.

SloMo is a digitally supported therapy that aims to overcome these barriers, and was developed by people with psychosis, designers, and psychologists. It supports people to notice worries and fast thinking habits. During therapy sessions, people learn to slow down and feel safer. Personalised spinning thought bubbles are slowed down using SloMo tips. An app provides access to helpful messages.

SloMo was previously tested in a randomised trial of 361 people attending mental health services. SloMo was found to be safe to use, with no adverse events linked to the software. People in the SloMo group had lower paranoia, and better confidence and wellbeing, over 6 months compared to people who just received their usual care. People found SloMo enjoyable and easy to use.

The next step is to evaluate if SloMo can be safely and effectively delivered by therapists working in NHS services. If SloMo works in routine care, the therapy will be made more widely available in the NHS.

An improved version of SloMo has been co-produced based on feedback. At least sixty therapists will be trained and supervised in 3 trusts to deliver SloMo to at least 150 people who fear harm from others. Safety, technical performance, uptake, engagement and acceptability data, alongside interviews with patients, therapists, and managers, will investigate how SloMo is used. Paranoia severity and wellbeing will be measured pre, post therapy, and at 12 months follow up, to find out if SloMo helps. Service use data will evaluate costs and savings.

Read the detailed description

DESIGN AND AIMS The study is a repeated measures design, with clinical outcome assessments pre-, post-delivery of SloMoR2, and a 12-month follow-up. The aim is to evaluate if SloMo is implementable and effective when delivered in routine care by therapists working in NHS routine services. Delivery with high and low intensity therapists will be evaluated, with the former holding doctorate or diploma therapy qualifications, and the latter representing graduate psychologists or the NHS's expanding workforce of psychological practitioners. Outcomes will be evaluated using questionnaires, software analytics, and medical record data (for adverse events, service use, and demographics when not self-reported). Interviews will be conducted with a subgroup of relevant stakeholders to understand their experiences of SloMo.

The project will be conducted in 3 NHS trusts. Each trust will have a local study team, funded by the research grant and directly employed by local services, to support training, supervision, and implementation. Design research has already been conducted in preparation for the study to support the co-production of an improved version of SloMo tailored for implementation (SloMoR2). The study will run for 42 months and consists of four stages:

1. Site set-up (month 1-3) Site set-up will be conducted to pilot the training, supervision, and technical support procedures that will ensure SloMoR2's performance, data protection and clinical safety.

2a. Process evaluation: Implementation (month 4 - 39) A mixed-method process evaluation will be co-produced to understand how SloMoR2 is experienced, including safety, engagement, adherence, acceptability, fidelity \& usability, and to identify barriers and enablers to implementation.

2ba. Effectiveness and cost-effectiveness (month 4 - 39) An evaluation will be conducted to establish the effectiveness and cost-effectiveness of SloMoR2 when delivered in routine care, including 12 month follow-up.

3. Analysis, resource development and dissemination (month 40 - 42) Findings will be summarised in consultation with our LEAP group. They will be written up in a plain English summary and as articles for submission to peer-review publications. Experiences of therapy delivery will inform any further refinements to the SloMoR2 software. Findings will also be used to support the co-design of an automated e-learning programme for therapists and develop a commercialisation strategy to assist being scaled up in the NHS.

SAMPLE AND RECRUITMENT Service user recruitment: The recruitment target for the effectiveness and cost-effectiveness analysis is to deliver SloMo to 150 service user participants (across Stage 1 and 2) who are: Aged ≥18 years, meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39), seeking therapy for paranoia, in contact with secondary care mental health services, and capable of providing informed consent to engage in therapy. People will be excluded if they: are at acute risk of harm to self or others, are unable to engage in therapy due to language barriers, and have a primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis. After 150 participants are recruited for the effectiveness/cost-effectiveness analysis, recruitment will continue until March 2027 for the implementation analysis.

Therapist recruitment, training, and supervision: In Stage 1, an initial cohort of therapists ('high intensity'; n = 5 per trust) will be selected from senior clinicians experienced in delivery and supervision of CBT for psychosis. Therapists will be required to complete training either through a 1-day workshop or using a self-guided online programme. They will subsequently be able to access on-demand clinical and technical supervision from their local study team as required to support SloMoR2 delivery. In Stage 2, at least 45 further 'high' and 'low' intensity therapists will be trained across the 3 sites. Training will be extended to 3 days for low intensity therapists. The local study team will liaise with local services to promote SloMo2 and support trainers to roll out training to other high and low intensity therapists.

Stakeholder recruitment: The experience of SloMo's delivery will be evaluated using subgroups of the therapist and participant samples recruited in Stages 1 and 2 (N = 60, and N = 150, respectively). This will involve interviewing subgroups of service users (n = 20) and therapists (n = 6) involved in SloMo's delivery, as well as senior managers (n = 5) and payers (stakeholders involved in the commissioning of mental health services; n = 5), about their experience of SloMo. The service users will be recruited by the local study team, and will be invited to interview post-therapy and at 12-month follow-up. The team will approach participants who consented to be contacted about further SloMo studies, once the participant has disengaged (therapist defined) or completed therapy. The four samples will be recruited to ensure a diverse range with respect to age, ethnicity, gender, site, and professional background (for staff interviews). All potential participants will be provided with a participant information sheet and given the opportunity to ask questions before signing the consent form.

PROCEDURE The local study team will initially conduct PPI consultation with their trust therapy workforce to scope readiness for adoption of SloMoR2. This work will identify implementation barriers and facilitators, to enable tailoring of implementation resources and strategies to site needs.

Trained therapists will identify potential participants and offer them SloMo, based on their clinical judgement. Following an initial introduction, participants will provide informed consent to receive SloMo and for their data to be collected for research purposes, with an optional opt-in for contact about further SloMo research. The burden of the informed consent process will be minimised where possible. This has been done by embedding the participant information sheet and consent form at the beginning of the SloMo webapp ('therapy platform'). Therapists will review this with potential participants and address any questions they have. Data storage and strategies for data protection will be emphasised, based on PPI feedback that this is a key area of concern. It will also be emphasised that service users will be free to withdraw their consent to engage in therapy at any time or to request that their data be deleted from the SloMo software or omitted from the research analysis.

If willing to proceed, participants' consent will be provided by indicating consent on the form. Participants will not sign the consent form with their name, to minimise the personally identifiable information stored in the software. Therapists will countersign and date the consent form. A copy of the countersigned consent form will be posted or sent electronically to the participant by the local SloMo team.

For the effectiveness analysis, pre and post therapy measures will be collected through the SloMo therapy platform at the first (R-GPTS (part B), short WEMWBS), second (GBO) and last therapy session (all), and will be repeated at 12-months post-consent. Sessional measures will be taken at each session and at 12-months follow-up. The local study team will collect demographic information from participants directly, and will extract adverse event and service use data from participants' medical record.

INTERVENTION SloMoR2 consists of up to 11 digitally supported therapy platform modules targeting paranoia and a mobile app for use outside of sessions. Therapy will be delivered according to the SloMo manual instructions for use. The therapy helps people learn to slow down for a moment to find ways of feeling safer and living well. Animated stories and interactive tasks support participants to learn how to apply SloMo tips to manage their worries, with in-session content synchronised to the mobile app which provides out of session support.

OUTCOMES

1a) Implementation To address the primary research question, is SloMoR2 implementable in routine care post-therapy, quantitative data will be gathered for the following primary outcomes: i) safety, measured by frequency of any unanticipated serious therapy and/or device-related adverse events, and ii) service user engagement, measured by the proportion of participants who are delivered 5 or more SloMo sessions ('minimum therapeutic dose'). In addition, data will be gathered for the following secondary outcomes: i) service user engagement, measured by the number of individuals who begin (1 or more sessions) and complete therapy (8 or more sessions, 'full course' as three modules are optional), ii) therapist uptake, measured by the percentage of therapists that receive SloMo R2 training who commence therapy with at least one participant, iii) adherence, measured by percentage completion of sessions started, iv) usage, service user usage of mobile app, v) acceptability, measured by the percentage of positive responses on the NHS Family and Friends Test, vi) fidelity, competence of therapy delivery (with a random selection of 10 sessions per site assessed by the local study lead), vii) stakeholder experience of implementation, based on qualitative interviews with service users, therapists, senior managers, and payers, and viii) usability, measured by the User Experience Survey (UES; Service user and therapist).

To address the secondary research question, is SloMoR2 implementable in routine care at 12-month, quantitative safety data and qualitative data regarding stakeholder experiences will also be gathered to 12-month follow up.

The qualitative interviews exploring user experience in participants who have been offered SloMo will be lived experience researcher-led. The qualitative interviews with therapists will explore experiences of training and delivery of SloMoR2 in more detail. Finally, senior managers and payers, who have and have not been involved in implementing SloMo, will be interviewed to understand their perspective on SloMo and its scale-up. All interviews will be audio recorded and transcribed for analysis. Participants will be reimbursed for their time according to INVOLVE guidelines.

1b) Effectiveness To address the primary research question, is SloMoR2 effective for paranoia and wellbeing when delivered in routine care post-therapy, participants will complete (via the SloMo therapy platform) three brief questionnaires at the beginning and end of therapy. The primary effectiveness outcome measure is the persecution subscale (part B) of the Revised Green Paranoid Thoughts Scale (RGPTS-B). Secondary effectiveness outcome measures are the short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS) and the Goal Based Outcome Scale. Sessional measures will be collected during therapy sessions to monitor progress, using four scales (rated from 0 - 100) of paranoia distress, fast and slow thinking, safety beliefs and confidence. To address the secondary research question, is SloMoR2 effective for paranoia and wellbeing when delivered in routine care at 12-months follow-up, participants will re-complete the RGPTS-B, SWEMWBS, GBOS and sessional measures.

1b) Cost-effectiveness To address the primary research question, is SloMoR2 cost-effective when delivered in routine care, costs and savings will be evaluated by the local study team extracting mental health service use data from participant medical records using the Client Service Receipt Inventory (CSRI), and QALYs derived from an algorithm applied to the Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B). Mental health service use data will cover the 6-month period prior to the intervention, and a 12-month period following consent (including both the intervention period and follow-up). This analysis will also incorporate the service use data collected for the SlowMoR1 trial as this will provide additional data to enhance the health economic modelling.

02

Conditions studied

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Affective Psychoses

Browse trials for

Keywords

  • Digital health
  • User-centred design
03

In context

Affective Disorders, Psychotic Reclassified

26 studies on the registry are indexed under Affective Disorders, Psychotic; 3 are open to participants now.

This study's planned enrollment of 150 is close to the median of 149 across 22 interventional studies indexed under Affective Disorders, Psychotic.

Browse Affective Disorders, Psychotic studies →

Lead sponsor

King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.

Compared within Affective Disorders, Psychotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia Spectrum and Other Psychotic Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39)
  • Seeking therapy for paranoia
  • In contact with secondary care mental health services
  • Capacity to provide to engage in therapy

Exclusion criteria

Exclusion Criteria:

  • Acute risk of harm to self or others
  • Unable to engage in therapy due to language barriers
  • Primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    SloMo

    Other: SloMo

Interventions

  • OtherSloMo

    SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face modules, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.

06

What researchers measure

Primary outcomes

  1. Implementation: Safety (adverse event incidence)

    Frequency of any unanticipated serious therapy and/or device-related adverse events

    Time frame: Pre-therapy to post-therapy.

  2. Implementation: Service user engagement

    Proportion of participants who are delivered 5 or more SloMo sessions ('minimum therapeutic dose')

    Time frame: Duration of therapy (typically up to 6 months)

  3. Effectiveness: Paranoid thoughts

    Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021). Range 0-40, higher scores indicate worse outcome.

    Time frame: Pre- to post-therapy.

  4. Cost-effectiveness: Service use

    Unit costs calculated from the Client Service Receipt Inventory (CSRI, Beecham and Knapp, 2001)

    Time frame: Pre-therapy to post-therapy.

  5. Cost-effectiveness: Paranoid thoughts

    QALYs derived from an algorithm applied to the Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021)

    Time frame: Pre-therapy to post-therapy.

Secondary outcomes

  1. Implementation: Service user engagement

    Number of individuals who begin (1 or more sessions) and complete therapy (8 or more sessions, 'full course' as three modules are optional)

    Time frame: Duration of therapy (typically up to 6 months)

  2. Implementation: Therapist uptake

    Percentage of therapists that receive SloMo R2 training who commence therapy with at least one participant

    Time frame: Duration of study (42 months)

  3. Implementation: Adherence

    Percentage completion of sessions started.

    Time frame: Duration of therapy (typically up to 6 months)

  4. Implementation: Usage

    Percentage of service users meeting mobile app adherence criteria (at least 1 home screen interaction after a minimum of 3 therapy sessions).

    Time frame: Pre- to post-therapy (typically up to 6 months)

  5. Implementation: Acceptability

    Percentage of positive responses on the NHS Family and Friends Test

    Time frame: Post-therapy (typically up to 6 months)

  6. Implementation: Fidelity

    Proportion of therapists meeting competence on the Revised Cognitive Therapy Scale (CTS-R) (of a random selection of 10 sessions scored per site, assessed by the local study lead).

    Time frame: Duration of study (42 months)

  7. Effectiveness: Paranoid thoughts - follow-up

    Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021). Range 0-40, higher scores indicate worse outcome.

    Time frame: Pre-therapy to 12 months follow-up

  8. Cost-effectiveness: Paranoid thoughts - follow-up

    QALYs derived from an algorithm applied to the Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021)

    Time frame: Pre-therapy to 12 months follow-up.

  9. Cost-effectiveness: Service use - follow-up

    Unit costs calculated from the Client Service Receipt Inventory (CSRI, Beecham and Knapp, 2001)

    Time frame: Pre-therapy to 12 months follow-up.

  10. Implementation: Safety (adverse event incidence) - follow-up

    Frequency of any unanticipated serious therapy and/or device-related adverse events

    Time frame: Pre-therapy to 12 months follow-up

  11. Implementation: Stakeholder experience of implementation

    Qualitative interviews with i) service users, ii) therapists, iii) senior managers, iv) payers

    Time frame: Duration of study (42 months)

  12. Implementation: Usability

    User Experience Survey (UES, Hardy et al, 2022; Service user and therapist)

    Time frame: Post-therapy (typically up to 6 months)

  13. Effectiveness: Wellbeing

    Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009). Range 7-35, higher scores indicate better outcome.

    Time frame: Pre- to post-therapy (typically up to 6 months)

  14. Effectiveness: Sessional measures

    Collected using visual analogue scales (rated from 0 - 100) of paranoia distress, fast and slow thinking, safety beliefs and confidence

    Time frame: Duration of therapy (typically up to 6 months)

  15. Effectiveness: Goal attainment

    Goal Based Outcome (GBO, Law et al, 2015). Range 0 (no progress) to 10 (goal has been reached), higher scores indicate better outcome.

    Time frame: Pre- to post-therapy (typically up to 6 months)

  16. Effectiveness: Wellbeing - follow-up

    Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009). Range 7-35, higher scores indicate better outcome.

    Time frame: Pre-therapy to 12 months follow-up

  17. Effectiveness: Sessional measures - follow-up

    Collected using visual analogue scales (rated from 0 - 100) of paranoia distress, fast and slow thinking, safety beliefs and confidence

    Time frame: Pre-therapy to 12 month follow-up

  18. Effectiveness: Goal attainment - follow-up

    Goal Based Outcome (GBO, Law et al, 2015). Range 0 (no progress) to 10 (goal has been reached), higher scores indicate better outcome.

    Time frame: Pre-therapy to 12 months follow-up

  19. Cost-effectiveness: Wellbeing

    QALYs derived from an algorithm applied to the Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009)

    Time frame: Pre- to 6 months post-therapy.

  20. Cost-effectiveness: Wellbeing - follow-up

    QALYs derived from an algorithm applied to the Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009)

    Time frame: Pre-therapy to 12 months follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — A fully anonymised, aggregate dataset will be shared with the wider research community. We will upload the data resulting from the study to ClinicalStudyDataRequest.com (CSDR), a consortium of clinical study sponsors/funders which is endorsed by Wellcome. In addition, other researchers may request access to IPD by contacting the study team, and will be shared in line with access criteria below.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be made available after completion of data collection and analysis, and publication of the main outcome papers, and will be available indefinitely via CSDR.

Access criteria: CSDR provides an ongoing forum where research proposals are checked and reviewed in 3 stages: 1) by the Wellcome Trust, which is the secretariat for the Independent Review Panel (IRP), 2) study funders sponsors and 3) the IRP. Direct requests for access must be accompanied by a protocol setting out the aims of the study for which the data are requested, very brief details of the credentials of team conducting the study (institutional affiliation, degrees or qualifications), methods outlined and appropriate ethical approval in place.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 23, 2024
StartActual
Oct 16, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568081
Collaborators
South London and Maudsley NHS Foundation Trust, Sussex Partnership NHS Foundation Trust, Northumberland, Tyne and Wear NHS Foundation Trust
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Oct 16, 2024
Primary completion
Sep 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Kathryn M Taylor
Contact
kathryn.taylor@kcl.ac.uk
07876876164
Amy Hardy
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion